Nice letter. There is little chatter as a lot of longs appear to have sold off. Most sold during the A/S increase news or during the last pump that brought ENDV to the 5s area. Also the true believers of the technology feel cheapened to see the SP move based on paid pump articles. I know of a few that also just grew impatient with an idle investment while other stocks were moving up.
The redesign of the tPEMF assets is important. The delivery of the signal to the pertinent area is critical to the success of the clinical trial. I am really curious to see how the Theracap was redesigned. I've stated this before but my guess is they don't want it to have a battery case with replaceable alkaline batteries. I believe they will make the battery fully encased like the current Sofpulse and will become a disposable item.
The MS tPEMF design has a patent. Don't know if they are redesigning it or only waiting to raise enough funds to initiate that trial.
RE: proteinuria PR. I believe they PR'd that prematurely. They may have PR'd it for the sake of future desire but they are most likely waiting for the current kidney pre-clinical to finish first.
Redeeming O/S convertible notes and NASDAQ uplist are the desires of most OTC companies. I'm not banking on seeing this anytime soon. Maybe in 2-3 years when/if they have successful human clinicals and Sofpulse revenue to meet the uplisting requirements.
Endonovo has a history of releasing PRs and then never mentioning them again. Like this one. Endonovo Therapeutics Developing Next-Generation Cell Therapy for Acute and Chronic Graft-Versus-Host Disease Using Cell-Enhancing Cytotronics Platform
They never PR any failures or stoppages of studies. It just remains silent...perhaps hoping we forget it was ever mentioned.
I hope this is not the case with the HDE desire.
I mention the GVHD situation as I see news today...another Therapeutics company is PRing updates on their phase 2 study using CBDs.
Brings back memories of past PRs that never amounted to anything. I would rather ENDV remain quiet than PR something once to never being mentioned again.
I am thinking this could be the case with the liver study. The initial PR on that was years ago and since then, have seen various statements that make it appear the pre-clinicals were initiating each time. I don't think they are having much success on that organ. That is ok. Can't get on base with every at bat. Just don't mislead investors.
News 
Market Data 
Discover 
